Need for a paradigm shift in cancer prevention and clinical oncology.
Every year approximately 3 million Europeans develop a cancer. Of these patients, 20-25% will suffer from cancer of the hepatogastrointestinal tract (the largest cancer group) and most of these individuals will die from the disease. Recent analysis from the American Cancer Society indicates that disease-related mortality from heart, cerebrovascular and infectious disease has decreased dramatically in the last 60 years, whereas the mortality of cancer remains unchanged. Despite recent improvements in the understanding of the biology, development and progression of human cancers, and the development of novel diagnostic and therapeutic approaches, most cancer patients are diagnosed in an advanced stage with a limited chance of cure. We hypothesize that there has been a dramatic shift in the treatment and, more importantly, prevention of heart, cerebrovascular and infectious diseases that has not yet reached oncology practice. We think that the shift from local to systemic therapy in combination with biomarker-guided detection of patients at risk leads to a reversion of current medical management: we do not treat the end-stage disease but rather follow the course of cancer development starting with risk assessment, followed by disease treatment and prevention of disease progression. Thus, we can prevent end-stage disease that cannot be treated curatively. Our two-step hypothesis should lead to a dramatic improvement of the prognosis of cancer patients.
Ebert
Matthias P
MP
Department of Medicine II, Klinikum rechts der Isar, TU München, Ismaninger Str. 22, 81675 München, Germany. matthias.ebert@lrz.tum.de
Schmid
Roland
R
Röcken
Christoph
C
D019468:Disease Management; D018450:Disease Progression; D005060:Europe / Q000453:epidemiology; D005544:Forecasting; D006801:Humans; D008495:Medical Oncology / Q000639:trends*; D009369:Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy*; D011379:Prognosis; D018570:Risk Assessment